DE69104991T2 - Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen. - Google Patents

Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.

Info

Publication number
DE69104991T2
DE69104991T2 DE69104991T DE69104991T DE69104991T2 DE 69104991 T2 DE69104991 T2 DE 69104991T2 DE 69104991 T DE69104991 T DE 69104991T DE 69104991 T DE69104991 T DE 69104991T DE 69104991 T2 DE69104991 T2 DE 69104991T2
Authority
DE
Germany
Prior art keywords
monohydrate
furoate
water
mometasone furoate
pregnadiene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69104991T
Other languages
German (de)
English (en)
Other versions
DE19875032I2 (de
DE69104991D1 (de
Inventor
Charles Eckhart
Teresa Etlinger
Nancy Levine
Pui-Ho Yuen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69104991(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69104991D1 publication Critical patent/DE69104991D1/de
Application granted granted Critical
Publication of DE69104991T2 publication Critical patent/DE69104991T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69104991T 1990-09-10 1991-09-06 Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen. Expired - Lifetime DE69104991T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10
PCT/US1991/006249 WO1992004365A1 (en) 1990-09-10 1991-09-06 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69104991D1 DE69104991D1 (de) 1994-12-08
DE69104991T2 true DE69104991T2 (de) 1995-04-20

Family

ID=24320279

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69104991T Expired - Lifetime DE69104991T2 (de) 1990-09-10 1991-09-06 Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DE1991604991 Active DE19875032I2 (de) 1990-09-10 1991-09-06 Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1991604991 Active DE19875032I2 (de) 1990-09-10 1991-09-06 Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen

Country Status (35)

Country Link
US (1) US6180781B1 (enExample)
EP (1) EP0548114B1 (enExample)
JP (1) JPH0725789B2 (enExample)
KR (1) KR960013445B1 (enExample)
CN (1) CN1030920C (enExample)
AT (1) ATE113604T1 (enExample)
AU (1) AU663471B2 (enExample)
BG (1) BG60755B2 (enExample)
CA (1) CA2091360C (enExample)
CZ (1) CZ281318B6 (enExample)
DE (2) DE69104991T2 (enExample)
DK (1) DK0548114T5 (enExample)
EE (1) EE02962B1 (enExample)
ES (1) ES2065701T3 (enExample)
FI (1) FI111078B (enExample)
HK (1) HK185996A (enExample)
HR (1) HRP920383B1 (enExample)
HU (1) HU213401B (enExample)
IE (1) IE67056B1 (enExample)
IL (1) IL99437A (enExample)
LU (1) LU90366I2 (enExample)
MX (2) MX9203396A (enExample)
MY (1) MY106644A (enExample)
NL (1) NL980012I2 (enExample)
NO (1) NO300548B1 (enExample)
NZ (1) NZ239711A (enExample)
OA (1) OA09772A (enExample)
PH (1) PH30443A (enExample)
PL (1) PL165803B1 (enExample)
PT (1) PT98905B (enExample)
SI (1) SI9111497A (enExample)
TW (2) TW229208B (enExample)
WO (1) WO1992004365A1 (enExample)
YU (1) YU48666B (enExample)
ZA (1) ZA917148B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL165803B1 (pl) * 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
EP2124944B1 (en) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
PL165803B1 (pl) * 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL

Also Published As

Publication number Publication date
IE913155A1 (en) 1992-03-11
PH30443A (en) 1997-05-09
HRP920383A2 (en) 1998-06-30
KR960013445B1 (ko) 1996-10-05
DE19875032I2 (de) 2007-04-19
NL980012I1 (nl) 1998-05-06
FI111078B (fi) 2003-05-30
HUT64361A (en) 1993-12-28
HU9300685D0 (en) 1993-06-28
CZ281318B6 (cs) 1996-08-14
US6180781B1 (en) 2001-01-30
IL99437A (en) 1995-05-29
MX9203396A (es) 1992-07-31
NO930693D0 (no) 1993-02-26
FI931031L (fi) 1993-03-09
AU663471B2 (en) 1995-10-12
NO300548B1 (no) 1997-06-16
PL165803B1 (pl) 1995-02-28
IE67056B1 (en) 1996-02-21
ZA917148B (en) 1992-08-26
MX9100990A (es) 1992-05-04
TW229208B (enExample) 1994-09-01
WO1992004365A1 (en) 1992-03-19
NO930693L (no) 1993-02-26
IL99437A0 (en) 1992-08-18
TW272195B (enExample) 1996-03-11
CN1059911A (zh) 1992-04-01
CA2091360A1 (en) 1992-03-11
HU213401B (en) 1997-06-30
CN1030920C (zh) 1996-02-07
EP0548114B1 (en) 1994-11-02
JPH05506667A (ja) 1993-09-30
LU90366I2 (fr) 1999-05-05
YU48666B (sh) 1999-06-15
EE02962B1 (et) 1997-02-17
HRP920383B1 (en) 2000-04-30
CA2091360C (en) 1997-04-08
BG60755B2 (bg) 1996-02-29
ATE113604T1 (de) 1994-11-15
PT98905B (pt) 1998-08-31
DK0548114T5 (da) 1995-01-30
ES2065701T3 (es) 1995-02-16
DE69104991D1 (de) 1994-12-08
MY106644A (en) 1995-07-31
NL980012I2 (nl) 2004-11-01
FI931031A0 (fi) 1993-03-09
JPH0725789B2 (ja) 1995-03-22
AU8497491A (en) 1992-03-30
EP0548114A1 (en) 1993-06-30
SI9111497A (sl) 1998-04-30
YU149791A (sh) 1994-01-20
NZ239711A (en) 1992-09-25
OA09772A (en) 1993-11-30
HK185996A (en) 1996-10-11
CZ38393A3 (en) 1994-01-19
PT98905A (pt) 1992-09-30

Similar Documents

Publication Publication Date Title
DE69104991T2 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
US6127353A (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
WO1998047872A1 (de) Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a
DE1906527B2 (de) Thioninderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, welche diese enthalten
DE3687171T2 (de) Kristallines triethylaminsalz von cefbuperazon.
DE69107098T2 (de) 2'-Deoxy-2'-Methylidenecytidin-dihydrat, Verfahren zu ihrer Herstellung und Mischmaterial.
DE3789264T2 (de) Beta-lactam-antibiotika.
DE69418953T2 (de) Kristalle einer antimikrobiellen Verbindung
DE2828074A1 (de) Form ii der 2-(4-chlorphenyl)- alpha -methyl-5-benzoxazolyl-essigsaeure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel
DE2654647A1 (de) Kristallines anhydrat von natrium-7- (d-2-hydroxy-2-phenylacetamido)-3- (1-methyl-1h-tetrazol-5-ylthiomethyl) -3-cephem-4-carboxylat und verfahren zu seiner herstellung
EP1116724B1 (de) Verfahren zur Herstellung von [IrCODCl]2
DE3044736C2 (enExample)
DE2655130C3 (de) Eine praktisch lösungsmittelfreie Kristallform des Cefacetril-Natriumsalzes
DE2522998A1 (de) Neues cephalosporinderivat, verfahren zu seiner herstellung und arzneimittel
DE830994C (de) Verfahren zur Herstellung von Doppelsalzen des Streptomycins
DE69221573T2 (de) Kristallines Etoposid-4'-Phosphat Diäthanolat
DE2241076B2 (de) Tetracyclinkomplex und dessen Salze, Verfahren zu dessen Herstellung und diesen Komplex enthaltende pharmazeutische Zusammensetzungen
DE3102026C2 (enExample)
DE1087598B (de) Verfahren zur Herstellung von 21-Amino-corticosteroiden
DE2549863C3 (de) Pyridoxyliden-p-amino-benzoesäurederivate, deren Herstellung und Verwendung
DE2214499A1 (de) Verfahren zur Herstellung von Phenazinderivaten
DE69513318T2 (de) Herstellung von Kristallen aus Diester Phosphat Monokazium-Salz
EP0041655A2 (de) 2-(2-Aminothiazol-4-yl)-N-(imidazolidin und perhydro-1,3-diazin-2-on-l-yl)-2-iminoacetylcephalosporinen der syn-Form und Verfahren zu deren Herstellung
DE1945619A1 (de) OEstrogene,wasserloesliche Konjugate und ihre Herstellung
DE1074590B (de) Verfahren zum Trennen von racemischen Lysergsäure- bzw Isolyserg saureabkommlmgen in ihre optischen Antipoden